Seneffe Manufacturing Facility – Shareholder Walkthrough
Telix Pharmaceuticals Limited provides a shareholder walkthrough of it’s recently acquired Seneffe manufacturing…
Read moreNews & Views
Telix Pharmaceuticals enters into Exclusive Licence Agreement with Osaka University
Telix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry…
Read more
Telix Quarterly Shareholder Update – CEO Presentation and Transcript of Investor Conference Call
Telix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruch’s conference call with…
Read more
Activity Report and Sales Note to Accompany Appendix 4C
Telix provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging…
Read more
AGM Notice of Meeting – Telix Pharmaceuticals Limited
Telix Pharmaceuticals provides notice of The Annual General Meeting of the Shareholders on Tuesday 12 May…
Read more
Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic
Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has entered into a commercial agreement with Cardinal…
Read more
Telix Completes Acquisition of European Radiopharmaceutical Production Facility
Telix is pleased to announce it has now completed the acquisition of a licensed radiopharmaceutical production facility in Seneffe,…
Read more
Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC
Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer…
Read more
Business Update : COVID-19
News,
Telix provides an update on the Company’s risk management assessment of the novel coronavirus (COVID-19)…
Read more